VIVS · XBRL financial data
VivoSim Labs financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (VIVS's year ends in late March)
| In thousands of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 0 | 1,500 | 370 | 109 | 144 | 131 |
| Cost of revenue | 0 | — | — | — | — | — |
| Cost of goods and services sold | 0 | — | — | — | 5 | 0 |
| Research and development | 1,103 | 3,320 | 8,885 | 5,498 | 5,025 | 4,189 |
| Selling, general and administrative | 15,723 | 9,659 | 9,216 | 9,697 | 7,730 | 7,429 |
| Operating income (loss) | (16,826) | (11,479) | (17,731) | (15,086) | (12,616) | (11,487) |
| Interest income | 15 | 8 | 454 | 405 | 140 | 267 |
| Interest expense | — | — | — | — | 10 | 12 |
| Other income (expense) | 6 | 25 | 0 | — | — | — |
| Income tax expense (benefit) | 2 | 2 | 2 | 2 | 2 | 2 |
| Net income (loss) | (16,826) | (11,448) | (17,259) | (14,671) | (2,488) | (13,843) |
| Earnings per share, basic‡ USD per share | — | (15.85) | (23.77) | (19.21) | (1.70) | (5.35) |
| Earnings per share, diluted‡ USD per share | — | (15.85) | (23.77) | (19.21) | (1.70) | (5.35) |
| Weighted average shares, basic‡ thousands of shares | — | 725 | 726 | 762 | 1,464 | 2,588 |
| Weighted average shares, diluted‡ thousands of shares | — | 725 | 726 | 762 | 1,464 | 2,588 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (March 2025); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (VIVS's year ends in late March)
| In thousands of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 37,364 | 28,675 | 15,301 | 2,901 | 11,312 | 5,024 |
| Short-term investments | — | 0 | — | — | — | — |
| Accounts receivable | 0 | 0 | 152 | 33 | 30 | 32 |
| Inventory | — | — | 0 | 297 | 0 | — |
| Prepaid and other current assets | 1,034 | 858 | 889 | 705 | 789 | 557 |
| Total current assets | 38,398 | 29,533 | 17,048 | 3,936 | 12,131 | 6,627 |
| Property and equipment, net | 381 | 662 | 902 | 669 | 419 | 206 |
| Right-of-use asset | 0 | 2,153 | 1,705 | 1,299 | 867 | 407 |
| Total assets | 39,917 | 33,296 | 20,313 | 6,349 | 14,650 | 7,386 |
| Accounts payable | 281 | 415 | 331 | 627 | 1,644 | 1,021 |
| Accrued liabilities | 440 | 489 | 2,848 | 727 | 1,226 | 981 |
| Total current liabilities | 721 | 1,383 | 3,671 | 1,860 | 3,737 | 2,785 |
| Lease liability, non-current | 0 | 1,704 | 1,313 | 888 | 421 | 0 |
| Total liabilities | 721 | 3,087 | 4,984 | 2,748 | 4,158 | 8,485 |
| Accumulated deficit | (296,291) | (307,739) | (324,998) | (339,669) | (342,157) | (356,000) |
| Total stockholders' equity | 39,196 | 30,209 | 15,329 | 3,601 | 10,492 | (1,099) |
| Total liabilities and equity | 39,917 | 33,296 | 20,313 | 6,349 | 14,650 | 7,386 |
| Common shares outstanding (cover page)‡ thousands of shares | 725 | 726 | 726 | 1,197 | 2,600 | 3,494 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (March 2025); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (VIVS's year ends in late March)
| In thousands of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (16,826) | (11,448) | (17,259) | (14,671) | (2,488) | (13,843) |
| Depreciation and amortization | 41 | 142 | 293 | 280 | 266 | 215 |
| Net cash from operating activities | (13,323) | (8,453) | (12,408) | (14,653) | (9,461) | (10,827) |
| Purchases of property and equipment | 405 | 409 | 396 | 42 | 13 | 0 |
| Net cash from investing activities | (393) | (409) | (966) | 816 | 9,025 | 94 |
| Proceeds from issuing common stock | 23,798 | 251 | 0 | 1,437 | 8,847 | 4,808 |
| Share repurchases | 1 | 0 | — | — | — | — |
| Net cash from financing activities | 23,835 | 205 | 0 | 1,437 | 8,847 | 4,445 |
| Net change in cash | 10,119 | (8,657) | (13,374) | (12,400) | 8,411 | (6,288) |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| VivoSim Labs | 1,670 | 18 | (3,213) | 14.9M | 0.5 quarters | 10-QJun 30, 2026 |
| Genprex | 15,154 | not reported | (5,139)* | 819,709 | 2.9 quarters | 10-QJun 30, 2026 |
| Orgenesis | 78 | 301* | (2,098)* | 9.8M | 0.0 quarters | 10-KDec 31, 2024 |
| Intensity Therapeutics | 9,529 | not reported | (2,340)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| Bolt Biotherapeutics | 12,860 | 5 | (6,540)* | 1.9M | 2.7 quarters | 10-QJun 30, 2026 |
| Zeo ScientifiX | 2,265 | not reported | not reported | 7.8M | — | 10-KTJun 30, 2026 |
| Sunshine Biopharma | 13,748 | 9,264 | (918)* | 3.9M | 15.0 quarters | 10-QJun 30, 2026 |
| Neuphoria Therapeutics | 19,866 | year only | 1,214* | 5.4M | — | 10-KJun 30, 2026 |
| Processa Pharmaceuticals | 196 | not reported | (1,996)* | 2.8M | 0.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.